[EN] NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS [FR] NOUVEAUX ANALOGUES NUCLÉOSIDIQUES SUBSTITUÉS PAR UN CYCLE AROMATIQUE BICYCLIQUE 6-6 UTILES COMME INHIBITEURS DE PRMT5
[EN] 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF M4 MUSCARINIC ACETYLCHOLINE RECEPTOR [FR] MODULATEURS ALLOSTÉRIQUES DE 3-(1H-PYRAZOL-4-YL)PYRIDINE DU RÉCEPTEUR MUSCARINIQUE M4 DE L'ACÉTYLCHOLINE
Rapid access to diverse, trifluoromethyl-substituted alkenes using complementary strategies
作者:James P. Phelan、Rebecca J. Wiles、Simon B. Lang、Christopher B. Kelly、Gary A. Molander
DOI:10.1039/c7sc05420c
日期:——
alkenes, cross-coupling or related functionalization processes at distal electrophilic sites can be executed without inducing Peterson elimination. Subsequent Lewis acidic activation affords functionalized α-trifluoromethyl alkenes. Likewise, the development of a novel α-trifluoromethylvinyl trifluoroborate reagent complements this approach and allows a one-step cross-coupling of (hetero)arylhalides to
[EN] COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE<br/>[FR] COMPOSÉS UTILES POUR MODIFIER LES TAUX D'ACIDES BILIAIRES POUR LE TRAITEMENT DU DIABÈTE ET DE MALADIES CARDIOMÉTABOLIQUES.
申请人:MERCK SHARP & DOHME
公开号:WO2018034917A1
公开(公告)日:2018-02-22
Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.
[EN] FATTY ACID SYNTHASE INHIBITORS<br/>[FR] INHIBITEURS DE L'ACIDE GRAS SYNTHASE
申请人:GLAXOSMITHKLINE LLC
公开号:WO2013052716A1
公开(公告)日:2013-04-11
Disclosed are compounds having Formula (I), or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R5, R6, R7, R8, R8a, R9 Y, and m are defined herein and methods of using the same.
This invention relates to spirocyclic piperidines according to Formula (I) and the use of spirocyclic piperidines for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of spirocyclic piperidines in the treatment of cancer.
This invention relates to spirocyclic piperidines according to Formula (I) and the use of spirocyclic piperidines for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of spirocyclic piperidines in the treatment of cancer.